AstraZeneca is a major research-intensive Pharmaceutical company with a substantial proportion and commitment of its R&D facilities in Sweden. The IMED Respiratory, Inflammation and Autoimmunity (RIA) unit with in AstraZeneca is engaged in the discovery and development of the innovative therapies to address unmet medical need in the broader RIA disease space. IMED RIA unit has established expertise and presence in the asthma and chronic obstructive pulmonary diseases therapeutic markets and a strong portfolio for academic collaborations supporting breakthrough science in these areas. Additionally , we have built a significant R&D track record over the last ten years in the discovery of potential therapeutics based on emerging science in the area of Respiratory, Inflammation and Autoimmunity research. Dr. K. Pardali is head of Biomarker discovery in the Target and Translational Science department, IMED RIA unit. She has held numerous positions in leading scientific research and project teams and successfully contributing to delivering novel science and transforming medicines to the IMED RIA portfolio.